Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
23
116
Ṁ999Ṁ470
2030
76%
chance
1D
1W
1M
ALL
In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy. Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).
To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein). The gene therapy must be for humans.
Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?
Get Ṁ200 play money
Related questions
Which applications of CRISPR technology will achieve regulatory approval for use in humans by 2030?
Will a vaccine for HIV be approved by the FDA by 2030?
66% chance
Will we be able to edit our own genomes by 2050?
68% chance
Will an AI-designed drug get FDA approval by the end of 2025?
33% chance
By 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
18% chance
Will a drug that didn't go through human clinical trials be approved by 2034?
28% chance
Will the FDA approve a disease-modifying treatment for Parkinson's disease before 2029?
59% chance
Will I receive any kind of gene therapy created using CRISPR before I die?
59% chance
Will Casgevy, the first cell therapy using CRISPR gene editing, have net sales >$100M in 2024?
25% chance
Will there be a CRISPR treatment for Ehlers-Danlos Syndromes before 2040?
52% chance